Hyperlipidemia due to oxymetholone therapy. Occurrence in a long-term hemodialysis patient.
Marked hypertriglyceridemia and hypercholesterolemia accompanied by angina and a left cerebral thrombosis occurred in a long-term hemodialysis patient following 5 1/2 weeks of oral treatment with oxymetholone, 100 mg/day, a synthetic androgen. After androgen therapy was discontinued, over a three-month period, plasma lipid values progressively decreased below pretreatment values, and clinical symptoms disappeared. During rechallenge with oxymetholone, serum lipid values increased substantially, and the lipoprotein pattern changed from a type IV to a type V. Detailed lipid studies showed subnormal postheparin lipolytic activity and a fast-migrating pre-beta-lipoprotein in a very-low-density lipoproteins (VLDL) fraction. Because of the data linking lipid abnormalities to atherosclerosis and the acceleration of atherosclerosis in long-term hemodialysis patients, great caution should be exercised in administering androgenic steroids to these patients.
D058186:Acute Kidney Injury / Q000628:therapy; D006801:Humans; D006937:Hypercholesterolemia / Q000139:chemically induced; D006949:Hyperlipidemias / Q000139:chemically induced*; D008074:Lipoproteins / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010110:Oxymetholone / Q000008:administration & dosage / Q000009:adverse effects*; D006435:Renal Dialysis; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D010110:Oxymetholone